文献速递造血干细胞移植与细胞治疗血栓与止血

儿童队列中移植相关血栓性微血管病及死亡的危险因素

Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort.
PubMed 文献 · Blood Adv · 2020-01-01

本研究为回顾性研究,纳入307例儿童造血干细胞移植患者,回顾移植后前100天记录。按Cho等(2010)和Jodele等(2014)标准回顾性诊断TA-TMA的比例分别为20%和36%,而临床医生诊断仅8例(2.6%)。符合TA-TMA标准者总生存显著更差、移植相关死亡率显著更高,校正合并症后符合TA-TMA标准(HR 10.9)和3/4级急性移植物抗宿主病(HR 3.5)仍与移植相关死亡率增加独立相关。

要点

  • 临床医生诊断TA-TMA仅8例(2.6%),回顾性应用Cho和Jodele标准诊断比例分别为20%和36%。
  • 符合TA-TMA标准者总生存显著更差(P < .0001),移植相关死亡率显著更高(P < .0001)。
  • 校正合并症后,符合TA-TMA标准(HR 10.9)和3/4级aGVHD(HR 3.5)与移植相关死亡率增加独立相关。

核心结论

  • 符合TA-TMA诊断标准与儿童造血干细胞移植后总生存更差和移植相关死亡率更高显著相关。
  • 校正合并症后,符合TA-TMA标准和3/4级急性移植物抗宿主病仍与移植相关死亡率增加独立相关。

研究设计与样本

  • 回顾性研究,纳入307例儿童造血干细胞移植患者,回顾移植后前100天记录。
  • 临床医生诊断的TA-TMA病例被纳入,并回顾性应用Cho等(2010)和Jodele等(2014)TA-TMA诊断标准。

主要发现

  • 8例(2.6%)由临床医生诊断TA-TMA;回顾性 review 中,20%符合Cho标准,36%符合Jodele标准。
  • 符合TA-TMA标准者总生存显著更差(P < .0001),移植相关死亡率显著更高(P < .0001)。
  • 校正合并症后,符合TA-TMA标准(HR 10.9;P = .0001)和3/4级aGVHD(HR 3.5;P = .01)仍与移植相关死亡率增加独立相关。
  • 在异基因造血干细胞移植受者中,与符合TA-TMA标准风险增加相关的因素包括≥2次HCT、并发3/4级aGVHD和并发感染。
  • 在符合TA-TMA标准的患者中,LDH≥2倍正常上限(P = .001)、需要≥2种降压药物(P < .0001)和急性肾损伤(P = .003)与移植相关死亡率显著增加相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transplant-associated thrombotic microangiopathy (TA-TMA) is a well-recognized complication of hematopoietic cell transplantation (HCT). Diagnosis is challenging and in the absence of a tissue biopsy, TA-TMA is provisionally diagnosed by meeting clinical criteria. In this study, we describe the prevalence, outcomes, and risk factors for meeting 2 different diagnostic criteria for TA-TMA and for increased transplant-related mortality (TRM). In this retrospective study of 307 pediatric HCT patients, records were reviewed for the first 100 days after HCT. Patients who were diagnosed with TA-TMA by a provider during this time were included. In addition, the Cho et al criteria (2010) and Jodele et al (2014) TA-TMA criteria were applied retrospectively. Eight patients (2.6%) were diagnosed with TA-TMA by their provider. However, on retrospective review, 20% and 36% met the Cho and Jodele criteria for TA-TMA, respectively. Overall survival was significantly worse (P < .0001) and TRM was significantly higher in patients who met criteria for TA-TMA (MC-TA-TMA) (P < .0001). After controlling for comorbid conditions, MC-TA-TMA (hazard ratio [HR], 10.9; P = .0001) and grade 3/4 acute graft-versus-host-disease (aGVHD) (HR 3.5; P = .01) remained independently associated with increased TRM. Among allogeneic HCT recipients, features associated with an increased risk for MC-TA-TMA included ≥2 HCT, concurrent grade 3/4 aGVHD and concurrent infections. Among patients who MC-TA-TMA, LDH ≥2 times the upper limit of normal (P = .001), the need for ≥2 antihypertensive medications (P < .0001), and acute kidney injury (P = .003) were associated with significantly increased TRM.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Schoettler M, Lehmann LE, Margossian S, et al. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort. Blood Adv. 2020. PMID: 32516415. doi:10.1182/bloodadvances.2019001242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。